Neumora Therapeutics Statistics
Total Valuation
NMRA has a market cap or net worth of $1.71 billion. The enterprise value is $1.37 billion.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NMRA has 161.56 million shares outstanding. The number of shares has increased by 368.32% in one year.
| Current Share Class | 161.56M |
| Shares Outstanding | 161.56M |
| Shares Change (YoY) | +368.32% |
| Shares Change (QoQ) | +0.37% |
| Owned by Insiders (%) | 5.78% |
| Owned by Institutions (%) | 47.68% |
| Float | 84.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.29 |
| P/TBV Ratio | 5.33 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.98, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.98 |
| Quick Ratio | 10.75 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -70.48% and return on invested capital (ROIC) is -37.20%.
| Return on Equity (ROE) | -70.48% |
| Return on Assets (ROA) | -34.92% |
| Return on Capital (ROIC) | -37.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.37M |
| Employee Count | 124 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NMRA has paid $446,000 in taxes.
| Income Tax | 446,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -18.43% |
| 50-Day Moving Average | 12.20 |
| 200-Day Moving Average | 11.81 |
| Relative Strength Index (RSI) | 48.06 |
| Average Volume (20 Days) | 958,366 |
Short Selling Information
The latest short interest is 10.46 million, so 6.47% of the outstanding shares have been sold short.
| Short Interest | 10.46M |
| Short Previous Month | 9.81M |
| Short % of Shares Out | 6.47% |
| Short % of Float | 12.31% |
| Short Ratio (days to cover) | 9.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -250.64M |
| Pretax Income | -273.79M |
| Net Income | -293.70M |
| EBITDA | -250.00M |
| EBIT | -250.64M |
| Earnings Per Share (EPS) | -$1.86 |
Full Income StatementBalance Sheet
The company has $341.31 million in cash and $2.75 million in debt, giving a net cash position of $338.56 million or $2.10 per share.
| Cash & Cash Equivalents | 341.31M |
| Total Debt | 2.75M |
| Net Cash | 338.56M |
| Net Cash Per Share | $2.10 |
| Equity (Book Value) | 320.74M |
| Book Value Per Share | 2.00 |
| Working Capital | 316.87M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$184.04 million and capital expenditures -$819,000, giving a free cash flow of -$184.86 million.
| Operating Cash Flow | -184.04M |
| Capital Expenditures | -819,000 |
| Free Cash Flow | -184.86M |
| FCF Per Share | -$1.14 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |